Andere Sprachen Ultimovacs ASA

Aktien

A2PKSD

NO0010851603

ULTI

Markt geschlossen - Oslo Bors Andere Börsenplätze 16:45:00 28.06.2024			% 5 Tage	% 1. Jan.
8.19 ^NOK	-0.12%		+4.33%	-93.33%

11.06.	Ultimovacs Asa gibt aktuelle Daten der Phase-I-Studie bei malignem Melanom bekannt	CI
07.05.	Transcript : Ultimovacs ASA, Q1 2024 Earnings Call, May 07, 2024

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Ultimovacs ASA announces revised terms of the employee share option program	24.06.
Ultimovacs ASA(OB:ULTI) dropped from S&P Global BMI Index	24.06.
Ultimovacs Asa Provides Update from Phase I Study in Malignant Melanoma	11.06.
Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab	11.06.
Ultimovacs : INITIUM Poster presentation at ASCO, June 1, 2024	01.06.
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	01.06.
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	01.06.
Ultimovacs : presentation per May 7, 2024	21.05.
Ultimovacs Q1 2024 - Survival mode	07.05.
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update	07.05.
Ultimovacs ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	07.05.
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation	30.04.
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24.04.
Ultimovacs ASA – Annual General Meeting held on April 18, 2024	18.04.
Ultimovacs to Reduce 40% of Workforce Amid Operational Adjustments	17.04.
Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program	16.04.
Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program	16.04.
Ultimovacs ASA Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program	16.04.
Ultimovacs - Invitation to Business Update on April 17, 2024	09.04.
Ultimovacs – Invitation to Business Update on April 17, 2024	09.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ultimovacs ASA

Aktien

A2PKSD

NO0010851603

ULTI

Andere Sprachen

Filter